Open Innovators Join free
News / 12 Nov 2026
Tech.eu · 12 Nov 2026 · Collaborations & pilots

Biomatter raises USD 18 million; AstraZeneca, BASF, Sanofi and Tereos buy its AI-designed enzymes

AI enzyme-design startup Biomatter raised an USD 18 million Series A led by Astanor. It has built custom enzymes for AstraZeneca, BASF, Sanofi and Tereos, and a commercial product uses an enzyme it developed with Thermo Fisher Scientific. The money funds a design and testing facility in Vilnius opening in 2027.

Why it matters: Custom enzymes now take weeks instead of months; R&D teams in pharma, chemicals and food can test such suppliers on a single reaction first.
Read the original at Tech.eu

Related collaborations

AstraZeneca × BiomatterBiomatter: custom enzymes for AstraZeneca
BASF × BiomatterBiomatter: custom enzymes for BASF
Sanofi × BiomatterBiomatter: custom enzymes for Sanofi
Tereos × BiomatterBiomatter: custom enzymes for Tereos
All collaborations